The CD3/CD20 bispecific antibody (bsAbs) can simultaneously bind to CD20 on B-cells and CD3 on T-cells to recruit and activate T-cells for tumor cell killing. As a popular target combination, CD3/CD20 bsAbs has garnered significant attention in the fields of hematological and solid tumors, including Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM). To accelerate drug R&D targeting CD3 and CD20, we've developed CD3 and full-length CD20 proteins, suitable for antibody drug development, screening, and quality control.

IBD is a chronic autoimmune digestive disease, including Ulcerative Colitis and Crohn's Disease. Unlock TL1A potential in IBD treatment with ACROBiosystems advanced TL1A Proteins, Functional Cells, Inhibitor Screening Kit. Designed for precise modulation and in-depth analysis, these tools empower researchers to explore TL1A-targeted therapies, paving the way for effective IBD solutions.